



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

TAK-960

Chemical Properties


CAS No. : 1137868-52-0

Formula: C₂₇H₃₄F₃N₇O₃

Molecular Weight: 561.6

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC ₅₀ values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.
Targets(IC ₅₀)	PLK
In vitro	CRC cell lines demonstrated a variable anti-proliferative response to TAK-960 with IC ₅₀ values ranging from 0.001 to >70.75 μmol/L. Anti-proliferative effects were sustained after removal of drug. Following TAK-960 treatment a highly variable accumulation of mitotic (indicating cell cycle arrest) and apoptotic markers was observed. TAK-960 treatment induced G2/M arrest and polyploidy. Six out of the eighteen PDX models responded to single agent TAK-960 therapy (TGI<20). The addition of TAK-960 to standard of care chemotherapy resulted in largely additive antitumor effects[1].
Cell Research	Fifty-five CRC cell lines and 18 PDX models were exposed to TAK-960 and evaluated for proliferation (IC ₅₀) and Tumor Growth Inhibition Index, respectively. Additionally, 2 KRAS wild type and 2 KRAS mutant PDX models were treated with TAK-960 as single agent or in combination with cetuximab or irinotecan. TAK-960 mechanism of action was elucidated through immunoblotting and cell cycle analysis[1].

Solubility Information

Solubility	DMSO: 35 mg/mL (62.32 mM), (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

A DRUG SCREENING EXPERT

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7806 mL	8.9031 mL	17.8063 mL
5 mM	0.3561 mL	1.7806 mL	3.5613 mL
10 mM	0.1781 mL	0.8903 mL	1.7806 mL
50 mM	0.0356 mL	0.1781 mL	0.3561 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Klauck P J , Bagby S M , Capasso A , et al. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer[J]. BMC Cancer, 2018, 18(1):136.
Hikichi Y, Honda K, Hikami K, et al. TAK-

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481